Comment
. 2007 Nov 7;99(21):1644; author reply 1644-6.
doi: 10.1093/jnci/djm175.
Epub 2007 Oct 30.
Re: Treatment of human epidermal growth factor receptor 2 overexpressing breast cancer xenografts with multiagent human epidermal growth factor receptor targeted therapy
- PMID: 17971534
- DOI: 10.1093/jnci/djm175
Item in Clipboard
Comment
Re: Treatment of human epidermal growth factor receptor 2 overexpressing breast cancer xenografts with multiagent human epidermal growth factor receptor targeted therapy
J Natl Cancer Inst.
.
No abstract available
Comment on
-
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.J Natl Cancer Inst. 2007 Feb 21;99(4):283-90. doi: 10.1093/jnci/djk050. J Natl Cancer Inst. 2007. PMID: 17312305 Clinical Trial.
-
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.J Natl Cancer Inst. 2007 May 2;99(9):694-705. doi: 10.1093/jnci/djk151. J Natl Cancer Inst. 2007. PMID: 17470737
-
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.J Natl Cancer Inst. 2007 May 2;99(9):727-37. doi: 10.1093/jnci/djk154. J Natl Cancer Inst. 2007. PMID: 17470740 Clinical Trial.
Similar articles
-
Re: Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors.J Natl Cancer Inst. 2000 Jun 7;92(11):943-4. doi: 10.1093/jnci/92.11.943a. J Natl Cancer Inst. 2000. PMID: 10841836 No abstract available.
-
Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer?Eur J Surg Oncol. 2001 Jun;27(4):335-7. doi: 10.1053/ejso.2000.1078. Eur J Surg Oncol. 2001. PMID: 11417974 No abstract available.
-
Meeting highlights: International consensus panel on the treatment of primary breast cancer.J Clin Oncol. 2002 Apr 1;20(7):1955-6; author reply 1956-7. doi: 10.1200/JCO.2002.20.7.1955. J Clin Oncol. 2002. PMID: 11919263 No abstract available.
-
Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.Minerva Ginecol. 2009 Dec;61(6):517-39. Minerva Ginecol. 2009. PMID: 19942839 Review.
-
Antiestrogens: the past and the future.Zentralbl Gynakol. 2002 Dec;124(12):551-8. doi: 10.1055/s-2002-40167. Zentralbl Gynakol. 2002. PMID: 12822068 Review. No abstract available.
Cited by
-
Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention.Oncologist. 2017 Dec;22(12):1431-1443. doi: 10.1634/theoncologist.2017-0148. Epub 2017 Sep 14. Oncologist. 2017. PMID: 28912152 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
